Kalohexis announced on April 17 that it will present a poster at the American Association for Cancer Research (AACR) Annual Meeting 2026, which takes place from April 17 to April 22 in San Diego, California.
The presentation will focus on the ongoing Phase 2 Paradox trial evaluating mifomelatide for cachexia in patients with advanced colorectal cancer. The topic is important as cachexia is a significant complication for many cancer patients and new therapies could improve patient outcomes.
Endevica Bio will present a trials-in-progress poster outlining the study design of the Paradox trial (NCT06937177). The trial began in the second quarter of 2025 and is now administered by Kalohexis. According to Kalohexis, primary endpoints include changes from baseline in body weight, incidence and severity of adverse events, and incidence of laboratory or vital sign abnormalities. Secondary endpoints involve changes from baseline in appetite and quality of life. The presentation is scheduled for April 21 from 9:00 a.m. to noon Pacific Time during the session “Phase II and Phase III Clinical Trials in Progress” at Poster Section 51; Poster Board #14.
Kalohexis describes itself as a clinical-stage biotechnology company focused on harnessing the melanocortin system to develop metabolic disease treatments. Its lead programs include an oral dual MC3R/MC4R agonist called 710GO for obesity and mifomelatide, a dual MC3R/MC4R antagonist intended for treating cachexia in advanced cancers.
The press release was distributed via PR Newswire, which operates across more than 170 countries and supports distribution in over 40 languages according to its official website. PR Newswire aims to provide global reach through its network of newsrooms and influencers according to its official website. The company features expert editors who offer round-the-clock support and SEO guidance as stated on its official website, collaborates with over half a million media outlets worldwide according to its official website, and offers services such as AI-enhanced content tools along with social sharing features as outlined on its official site.
Further information about Kalohexis’ research programs can be found on their corporate website or through their investor contact.
